NCT00100789 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 63
- units
- Participants
- groups
- description
- Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR. Eligible patients who received any treatment were included in baseline measures.
- id
- BG000
- title
- Gemcitabine and Paclitaxel
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 40.7
- upper Limit
- 82.9
- value
- 63.1
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Female
- measurements
- group Id
- BG000
- value
- 50
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 56
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 50
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- title
- Lip/Oral Cavity
- categories
- measurements
- group Id
- BG000
- value
- 4
- title
- Nasopharynx
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Oropharynx
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- Salivary glands
- categories
- measurements
- group Id
- BG000
- value
- 2
- title
- Hypopharynx
- categories
- measurements
- group Id
- BG000
- value
- 16
- title
- Larynx
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Paranasal Sinuses
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Other/Unknown
- param Type
- NUMBER
- title
- Primary Site
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Newly Diagnosed
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Persistent
- categories
- measurements
- group Id
- BG000
- value
- 50
- title
- Recurrent
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- Not Reported
- param Type
- NUMBER
- title
- Disease Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 24
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 39
- title
- 1
- description
- Performance status is graded according to the Zubrod Performance Status Scale. Patients with a performance status of 0 are fully active, able to carry on all pre-disease performance without restriction. Patients with a performance status of 1 are restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.
- param Type
- NUMBER
- title
- Performance Status
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 63
- units
- Participants
- groups
- description
- Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR. Eligible patients who received any treatment were included in baseline measures.
- id
- BG000
- title
- Gemcitabine and Paclitaxel
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 40.7
- upper Limit
- 82.9
- value
- 63.1
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Female
- measurements
- group Id
- BG000
- value
- 50
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 56
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 50
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- title
- Lip/Oral Cavity
- categories
- measurements
- group Id
- BG000
- value
- 4
- title
- Nasopharynx
- categories
- measurements
- group Id
- BG000
- value
- 13
- title
- Oropharynx
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- Salivary glands
- categories
- measurements
- group Id
- BG000
- value
- 2
- title
- Hypopharynx
- categories
- measurements
- group Id
- BG000
- value
- 16
- title
- Larynx
- categories
- measurements
- group Id
- BG000
- value
- 3
- title
- Paranasal Sinuses
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Other/Unknown
- param Type
- NUMBER
- title
- Primary Site
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Newly Diagnosed
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Persistent
- categories
- measurements
- group Id
- BG000
- value
- 50
- title
- Recurrent
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- Not Reported
- param Type
- NUMBER
- title
- Disease Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 24
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 39
- title
- 1
- description
- Performance status is graded according to the Zubrod Performance Status Scale. Patients with a performance status of 0 are fully active, able to carry on all pre-disease performance without restriction. Patients with a performance status of 1 are restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.
- param Type
- NUMBER
- title
- Performance Status
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle